Cannabidiol in the management of in-patient cannabis withdrawal: Clinical case series
- Publication Type:
- Journal Article
- Future Neurology, 2017, 12 (3), pp. 133 - 140
- Issue Date:
Files in This Item:
|2017 Pokorski_CBD_Future Neurol 12 133140 (002).pdf||Published Version||1.06 MB|
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
© 2017 Future Medicine Ltd. Aim: To assess the feasibility of the use of cannabidiol (CBD) for the management of cannabis withdrawal. Patients & methods: Eight participants were admitted to an in-patient detoxification facility for a 7-day open-label trial of CBD. Five participants received 600 mg of CBD and three participants received 1200 mg of CBD. Participants returned for a 28-day follow-up interview. Results & conclusion: CBD was well tolerated by all participants. Five completed the full treatment period and abstinence was maintained by four participants at day 28 follow-up. All those receiving the higher dose completed treatment and achieved abstinence at follow-up. This pilot study suggests that further exploration of CBD as a pharmacological adjunctive therapy for cannabis withdrawal and dependence is warranted. Registration ACTRN1261400024866.
Please use this identifier to cite or link to this item: